Redhill Biopharma (RDHL) News Today $2.19 +0.06 (+2.82%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$2.13 -0.06 (-2.92%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide studyJuly 2, 2025 | msn.comRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerJuly 1, 2025 | prnewswire.comRedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Ltd. (RDHL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18, 2025 | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17, 2025 | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17, 2025 | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16, 2025 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | prnewswire.comRedHill Biopharma to submit UK MAA for TaliciaMarch 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing AuthorisationMarch 18, 2025 | finanznachrichten.deRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationMarch 18, 2025 | prnewswire.comRedHill Biopharma announces plans to advance program for Crohn’s diseaseMarch 13, 2025 | markets.businessinsider.comRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsMarch 12, 2025 | prnewswire.comRedHill Presents Business Update at the Sachs' European Life Sciences CEO ForumFebruary 27, 2025 | prnewswire.comRedHill and Hyloris sign agreement for Bekinda’s developmentFebruary 26, 2025 | msn.comRedHill Biopharma licenses RHB-102 for global commercialization to HylorisFebruary 25, 2025 | markets.businessinsider.comRedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesFebruary 25, 2025 | prnewswire.comEarnings call transcript: RedHill Biopharma Q1 2022 sees revenue dipFebruary 7, 2025 | msn.comRedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer TreatmentFebruary 6, 2025 | markets.businessinsider.comRedHill tests opaganib with Bayer's drug in prostate cancer studyFebruary 4, 2025 | msn.comRedHill Biopharma Ltd.: RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerFebruary 4, 2025 | finanznachrichten.deRedHill Biopharma begins Phase 2 study of prostate cancer combinationFebruary 4, 2025 | markets.businessinsider.comRedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerFebruary 4, 2025 | prnewswire.comRedHill stock rises on expanded Medicare coverageJanuary 21, 2025 | msn.comRedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedJanuary 21, 2025 | prnewswire.comRadioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentDecember 10, 2024 | prnewswire.comRedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtDecember 2, 2024 | prnewswire.comRedHill Biopharma to Present Opaganib at U.S. Defense ConferenceOctober 29, 2024 | markets.businessinsider.comRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDOctober 28, 2024 | prnewswire.comRedHill Biopharma and Duke Collaborate on Opaganib DevelopmentOctober 22, 2024 | markets.businessinsider.comRedHill Biopharma signs research pact with Duke University School of MedicineOctober 22, 2024 | markets.businessinsider.comRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryOctober 22, 2024 | prnewswire.comRedHill: BARDA Selects Opaganib For Development & Funding As Medical Countermeasure To Treat EbolaOctober 14, 2024 | markets.businessinsider.comRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentOctober 14, 2024 | prnewswire.comRedHill Biopharma Secures Opaganib COVID-19 PatentOctober 1, 2024 | finance.yahoo.comRedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansOctober 1, 2024 | prnewswire.comRedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041September 30, 2024 | prnewswire.comRedHill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Decline in Short InterestSeptember 26, 2024 | marketbeat.comRedHill Biopharma (NASDAQ:RDHL) Stock Price Passes Below 200-Day Moving Average of $10.89September 12, 2024 | marketbeat.comRedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesSeptember 9, 2024 | prnewswire.comRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 5, 2024 | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $11.02September 4, 2024 | marketbeat.comREDHILL B.AD 10000/IL-,01 (2RH.MU)September 3, 2024 | au.finance.yahoo.comNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 MortalitySeptember 3, 2024 | prnewswire.com Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Media Mentions By Week RDHL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RDHL News Sentiment▼1.871.01▲Average Medical News Sentiment RDHL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RDHL Articles This Week▼11▲RDHL Articles Average Week Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cingulate News Today Marker Therapeutics News Today BioVie News Today Q32 Bio News Today Mannatech News Today ProPhase Labs News Today Reviva Pharmaceuticals News Today Carisma Therapeutics News Today Lipocine News Today Gelteq News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RDHL) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
